Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ-Belite Bio shares fall as FDA extends review period for eye disease drug

BUZZ-Belite Bio shares fall as FDA extends review period for eye disease drug

路透社路透社2026/11/20 13:25
Show original

- ** Belite Bio (BLTE.O) shares fell 10.6% premarket to $135

** The company stated that the U.S. Food and Drug Administration (FDA) has extended the review period for its investigational drug tinlarebant for the treatment of Stargardt disease type 1 by three months

** The new action date is May 12, 2027

** It added that if the FDA does not identify major deficiencies during the review, the agency expects to provide proposed labeling and any potential post-marketing requirements by April 12

** Stargardt disease type 1 is an inherited retinal disorder caused by ABCA4 gene mutations, resulting in progressive loss of central vision

** As of the previous trading session close, the share price had fallen 5.6%


(To help non-English speakers, Reuters has automated its news translation into several other languages. As there may be mistakes in automated translations, or important context may be missing, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters accepts no responsibility for any damage or losses caused by use of automated translation functionality.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!